Navigation Links
Intarcia Therapeutics, Inc. Announces Acceptance of ITCA 650 Phase 1b Study for Late-Breaker Presentation at the American Diabetes Association 69th Scientific Sessions
Date:5/27/2009

First clinical study evaluating DUROS(R) continuous delivery of exenatide for the treatment of type 2 diabetes

HAYWARD, Calif., May 27 /PRNewswire/ -- Intarcia Therapeutics, Inc. today announced it will present clinical data from a phase 1b study of ITCA 650 (DUROS(R) continuous delivery of exenatide) for the treatment of type 2 diabetes as a late-breaker at the Annual Conference of the American Diabetes Association in New Orleans, LA (June 5-9, 2009). The study was conducted at multiple centers in the United States and evaluated a 4-week course of ITCA 650 treatment among 44 patients (n= 10-12 patients/dose arm) with type 2 diabetes.

(Logo: http://www.newscom.com/cgi-bin/prnh/20050301/SFTU126LOGO)

ITCA 650 Late-Breaker Abstract 4-LB in Category 01-C Clinical Therapeutics/ New Technology - Other Drug Delivery Systems:

A Phase 1b Study of ITCA 650: Continuous Subcutaneous Delivery of Exenatide via DUROS(R) Device Lowers Fasting and Postprandial Plasma Glucose - Luskey, K., McNally, J., Dahms, J., Logan, D., Weiner, G., Denham, D. and Alessi, T.

"We are very pleased the ADA scientific reviewers selected our study for presentation as a late-breaker," said Alice Leung, President & CEO of Intarcia Therapeutics, Inc. "Our team worked very hard to advance this program from an idea to clinical evaluation in under 18 months. In continuing this brisk pace, we expect to begin a phase 2 study of ITCA 650 in the second half of this year."

The late-breaker abstract describes the dose-ranging design of the study and preliminary results from the two lower doses of 10mcg/day and 20 mcg/day through the first two weeks of treatment. Based on the favorable tolerability of DUROS continuous delivery of exenatide on the lower doses, patients have been enrolled to two higher d
'/>"/>

SOURCE Intarcia Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Intarcia Therapeutics, Inc. Announces Appointment of Kenneth Luskey, M.D. as Vice President, Clinical Research
2. Prospect Therapeutics, Inc.s GCS-100 Inhibited Blood Vessel Formation in a Variety of Cancer Models
3. Cell Therapeutics, Inc. (CTI) to Present at 2009 BIO International Convention
4. Prospect Therapeutics, Inc. Assigns All Its Assets to Joseph F. Finn, Jr., C.P.A. for the Benefit of Its Creditors
5. Cell Therapeutics, Inc. (CTI) to Report 2009 First Quarter Financial Results on May 7
6. Oxygen Biotherapeutics, Inc. Signs Supply Agreement for Clinical-Grade Oxycyte for Clinical Trials and Future Needs
7. Cell Therapeutics, Inc. Announces Single Institutional Investor Purchases $15 Million of Preferred Stock
8. Oxygen Biotherapeutics, Inc. CEO Posts New Blog Entry
9. Stockholder Suits Related to TorreyPines Therapeutics, Inc. Dismissed
10. Webcast Alert: Oxygen Biotherapeutics, Inc. Investor Meeting in Zurich, Switzerland
11. Oxygen Biotherapeutics, Inc. Adds Oxycyte TBI Clinical Trial Sites in Israel
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... A study has been launched to test ... track could help to tackle the problem of obesity.  This ... GP surgery based in Stowmarket) and academics at University Campus ... Telemetry technology, which is inspired by equipment used to collect ...
(Date:1/15/2014)... DTS Language Services, Inc . is ... for Life Science organizations who need document translations. Clients ... of their documents in advance with a selection of nearly ... translations, often a critical factor in clinical and scientific fields, ...
(Date:1/15/2014)... 15, 2014 TaiGen Biotechnology Company, Limited ("TaiGen") today ... R-Pharm, a leading Russian pharmaceutical company, to develop and ... Russian Federation , Turkey ... is a novel antibiotic for the treatment of bacterial ...
(Date:1/14/2014)... Communications, a leading provider of strategic communications services to corporations and ... the United States and Europe ... JD, is returning to the firm,s Washington, D.C. ... more than two years of service as Associate Commissioner for the ...
Breaking Biology Technology:Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 2Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 3Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 4DTS Improves Efficiency for Life Science Document Translations 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 4Former FDA Associate Commissioner Returns To 3D Communications 2
... Benefit From Hidden Scar Surgical Technique ... Performed Through the Belly Button, ... successful completion of what are believed to be the,first ever ... by Dr. Jeffrey Cadeddu, associate professor of,urology and radiology at ...
... Hotel in New York on Thursday, ... ... (Nasdaq:,FVRL), a biopharmaceutical company developing patient-specific, active,immunotherapies for the treatment of ... Officer, will present at,the NewsMakers in the Biotech Industry investment conference ...
... DNA sequencing equipment market,is expected to grow nearly ... million to $528 million as competition intensifies and ... a new report by,Kalorama Information. The DNA ... last,several years, with one dominant vendor and relatively ...
Cached Biology Technology:Novare Announces First Ever Single Port Laparoscopic Kidney Removal (Nephrectomy) Using RealHand(TM) HD Instruments 2Favrille CEO to Present at NewsMakers in the Biotech Industry Investment Conference 2DNA Sequencing Equipment Market to Fragment and Grow as Competition, New Technologies Develop 2
(Date:7/9/2014)... With over 100 diseases that can attack soybean crops, ... the most wanted list? University of Illinois scientists cite ... research is needed on the fungus that causes charcoal ... damp growing conditions but Macrophomina phaseolina , the ... drought conditions. , "As the climate continues to change ...
(Date:7/9/2014)... with pain and fever but often can be defeated with ... and hard to beat. Now, scientists have built a new ... pyramids. Published in the journal ACS Applied Materials & ... and kill more of them than medicine alone. , David ... can lie in wait, undetectable in the human body or ...
(Date:7/9/2014)... may be on the verge of an economy driven by ... than coal and is undergoing a production boom. It has ... recent research is casting serious doubts over just how climate-friendly ... Engineering News (C&EN), the weekly news magazine of the ... senior correspondent at C&EN, explains that when burned as a ...
Breaking Biology News(10 mins):Climate change provides good growing conditions for charcoal rot in soybeans 2Climate change provides good growing conditions for charcoal rot in soybeans 3
... have identified 23 new longevity genes by screening the ... used as a model organism in genetics studies. The ... Genetics. , Each of the 23 genes somehow normally ... them increases lifespan. For example, the worm's lifespan doubles ...
... Unlike most mammals, cats--both domestic and wild--are indifferent ... explains the molecular mechanism behind their strictly carnivorous ... it molecularly," says Joseph Brand, senior author of ... Chemical Senses Center. , Scattered on mammalian tongues ...
... invaluable decision-making tools for public health officials. As ... 2001, models can be useful in two ways: ... infection and they can allow the comparison of ... implicit assumptions that may systematically bias their predictions, ...
Cached Biology News:Field of beams - Novel system uses polarized light pulses to reveal crop health 2
Conveniently document gels, films and membranes with a high quality thermal printer. , Compact, footprint printer , Supplies 256 gray scale for high resolution, archive-quality thermal film prints...
... ICE-LAP3 Mch3 Lyophilized solid. ... enzyme regulation and kinetics, cleavage of target substrates, and ... protein. One unit is defined as the ... Ac-DEVD-pNA Cat. No. 235400 per hour at 37 C ...
Request Info...
Bovine Coronary Artery Endothelial Cells (BCAEC) (>500,000 cells)...
Biology Products: